Newgenivf Group Limited — Form 6-K
Reporting period: September 2026. Filed September 30, 2026. This report describes a securities offering; it does not provide operating results for the period.
Offering and key financial terms
- The company closed a best-efforts public offering on September 30, 2026, issuing 17,857,143 Class A ordinary shares or pre-funded warrants: 125,000 shares and warrants to purchase up to 17,732,143 shares.
- Gross proceeds were approximately $1.25 million, before placement-agent fees and other offering expenses. The net proceeds are not stated.
- Aegis Capital Corp. served as exclusive placement agent and is entitled to a cash fee equal to 8.0% of gross proceeds, plus reimbursement of certain expenses.
- The filing provides no revenue, profit, cash flow, margin, debt-balance, or liquidity metrics.
Use of proceeds and other material terms
The company expects to use net proceeds for investment in K25.ai, restructuring debt securities, working capital—including manufacturing and deployment of Nodexus machines in its cell-sorting business—and general corporate purposes. These are stated intentions, not reported expenditures.
Company officers, directors, and employees holding ordinary shares agreed, subject to customary exceptions, not to dispose of their beneficially owned shares for 60 days after the offering closed.
Changes, outlook, and risks
The filing does not provide a comparable prior-period offering or financial results, so period-over-period changes cannot be assessed. Management’s forward-looking statements regarding use of proceeds are subject to market conditions, the company’s ability to deploy funds as planned, and other risks described in its SEC filings. The company says it undertakes no obligation to update these statements except as required by law.
Investor facts to verify
- Confirm final offering expenses, placement-agent reimbursements, and net proceeds received.
- Review the pre-funded warrant terms and potential dilution from exercise.
- Track the actual allocation of proceeds to K25.ai, debt restructuring, and Nodexus manufacturing and deployment.
- Review the attached placement agent agreement and the referenced prospectus and press releases for additional terms and disclosures.